Whitehead was most recently group communications director at Prudential and he has previously held senior roles at Barclays and Allied Domecq. Earlier in his career he spent 10 years at Glaxo and Eli Lilly at UK, European and international level. He has in-depth experience of working in regulated industries, has led significant change and modernisation programmes and has extensive experience of developing teams.
ABPI president Simon Jose said: ‘As chief executive, Stephen brings skills and experiences that will enable us to meet the challenges ahead with energy and creativity. His expertise in effective stakeholder relations acquired over a 25-year career in policy, public affairs and communications will provide effective leadership to ensure we work in partnerships that benefit patients, the NHS and the pharmaceutical industry.’
ABPI appoints Stephen Whitehead as chief executive
Takes up the post on 1 June
You may also like
Media
Life Science Industry Coalition position paper released
The associations representing the European and British life science industry (AESGP, ABPI, BIA, BGMA, EBE, EFPIA, EUCOPE, EuropaBio, Medicines for Europe, PAGB, Vaccines Europe) have launched a joint policy document on the potential impact of the UK’s exit from the EU
Media
Safeguarding public health must be number one priority
To coincide with the House of Commons Health Select Committee on <i>Brexit: the regulation of medicines, medical devices and substances of human origin</i>, the Association of the British Pharmaceutical Industry (ABPI) and the BioIndustry Association (BIA) have published new research on the public health implications of Brexit
Research & Development
New Lung Health Taskforce to tackle Britain’s third biggest killer
The Association of the British Pharmaceutical Industry (ABPI) and the British Lung Foundation (BLF) have launched a new Taskforce for Lung Health that will work, in collaboration, to produce a new national 5 year prevention, diagnosis and treatment plan for lung health
